The Digital Health display category at CeBIT 2018 in Hannover is bang on trend - everywhere you look there are new solutions and products that, although not a cure in their own right, make it much easier to treat diseases. In fact, the subjective perception of quality of life can often be just as important as objective lab values, particularly when it comes to complex illnesses. TWT Digital Health GmbH has therefore developed a software package for the German subsidiary of international pharmaceutical group Lilly that is designed to help medical specialists analyze and record the quality of life among patients with hypopituitarism.
A deficiency or a complete lack of one or more hormones produced by the pituitary gland usually leads to serious medical complications. What's more, it is difficult to assess the effects of hormone therapies, particularly among adults, because the symptoms cannot easily be measured. That is why TWT Digital Health GmbH set out to develop a new tool - the "QLS-H-Tracker" - which is primarily designed to record quality of life in a more objective way. A scientifically proven questionnaire is used to convert the data collected in the treatment center into a score, which is then used as a basis for adjusting the growth hormone dosage. "Quality-of-life scores are an important tool for many indications," explains Tobias Klingenfuss, Project Manager at TWT Digital Health. Dr. Tilo Kramer, Senior Brand Manager HGH at Lilly Deutschland, is impressed: "TWT Digital Health has both the necessary IT expertise and a profound knowledge of both endocrinology and regulations. That made our collaboration much easier. We were able to tackle challenges much more quickly than we otherwise could have done. The result speaks for itself."
TWT Digital Health GmbH (69123 Heidelberg, Germany)